Cell Therapy Information
Streamline the path from discovery to cure
As you move your translational stem cell, tissue engineering, and immunotherapy research toward the clinic, your product selection, lab process, documentation, and quality assurance steps become more demanding. This collection of resources will help you gain a better understanding of cell therapy research, feel confident at every step, and maximize your time, effort, and outcomes.
Enabling hope for cancer patients through CAR-T cell therapy and Dynabeads technology
Nicole Gularte was diagnosed with acute lymphoblastic leukemia. After participating in multiple clinical trials, she qualified for a new clinical trial utilizing CAR-T cell therapy, which uses Thermo Fisher’s Gibco CTS Dynabeads technology.
CTS Mini-documentary series
In this 7-part series, hear from four experts with backgrounds in stem cell therapy and immunotherapy research, cell therapy manufacturing, and clinical development on their unique perspectives on the opportunities and challenges facing the cell therapy industry.
Webinar: New viral and non-viral platforms for T-cell engineering
In this webinar, we will highlight the different viral and non-viral delivery approaches used in T cell engineering for cell and gene therapy applications including LV-MAX Lentiviral Production System and novel gene editing tools for primary T cells.
Webinar: Comparison of the Teratoma assay and in vitro surrogate tests for assessment of pluripotency of human pluripotent stem cells
For optimal use of human induced pluripotent stem cells (hiPSCs) it is essential to identify lines that are fully reprogrammed and of high quality with proven pluripotency in terms of differentiation. This presentation will compare different solutions for the assessment of that pluripotency.
Interview: Addressing the Challenges of Commercial-Scale Manufacture of Viral Vectors for CAR-T Therapies
In this interview with Xavier de Mollerat du Jeu, Director of R&D for Cell Biology and Transfection at Thermo Fisher Scientific and Calley Hirsch, CCRM, we learn about the critical importance of scalable viral vector manufacture to support the commercial-scale production of CAR-T therapies. They express challenges and limitations with current CAR-T manufacturing processes. Both speakers end with sharing their thoughts on new technologies and tools in development to specifically address viral vector supply issues.
Search all learning center resources
The CTS product line is designed for use in cell therapy research applications and includes media, reagents, growth factors, enzymes, selection beads, and devices, which are manufactured in compliance with 21 CFR Part 820 Quality System Regulation and/or are certified to ISO 13485 and ISO 9001.
For Research Use Only. Not for use in diagnostic procedures.